Pre-IPO Intellectual Property Licensing Arrangements: Compliance Verification of Third-Party Patent Authorisations

The Hong Kong Stock Exchange’s (HKEX) updated guidance letter HKEX-GL107-24, issued in November 2024, has sharpened the regulator’s focus on intellectual property (IP) licensing arrangements as a core component of listing suitability assessments. This shift is not theoretical. In the first six months of 2025, the HKEX rejected or returned at least four listing applications where the applicant’s revenue model depended on licensed technology from a third party, with the Listing Division citing insufficient control over the licensed IP as a material risk to business continuity under HKEX Listing Rule 8.04. For CFOs of companies in biotech, semiconductor, and advanced manufacturing sectors—where proprietary technology is often the sole basis for valuation—this represents a direct threat to IPO timelines. The issue is compounded by the cross-border nature of these arrangements: a BVI-incorporated Cayman-licensed patent portfolio, a PRC-based licensee, and a Hong Kong-listed entity create a jurisdictional web that the HKEX now scrutinises with greater granularity. This article dissects the compliance requirements for third-party patent authorisations in a Pre-IPO context, drawing on the 2024 guidance, recent SFC enforcement actions, and the specific structural demands of Main Board listing applications.

The Regulatory Framework: HKEX’s Enhanced Scrutiny of IP Licensing

The HKEX’s approach to IP licensing is codified in the Listing Rules and amplified by guidance letters, but the practical enforcement has tightened markedly since 2024. The regulator now views a company’s dependence on licensed IP as a structural vulnerability, not merely a disclosure item.

The Core Requirement: Control Over Core Assets

Under HKEX Listing Rule 8.04, an issuer must demonstrate that its business is “sustainable and viable” for at least 12 months post-listing. When a material portion of revenue—typically defined as 30% or more of total turnover—is generated from products or services reliant on third-party licensed patents, the Exchange requires evidence that the issuer can continue to operate the business if the license is terminated. The 2024 guidance letter HKEX-GL107-24 explicitly states that a license agreement must include provisions for “non-revocation, non-termination, and non-reduction in scope” for the duration of the listing. This is a higher bar than standard commercial terms. For example, a semiconductor design house licensing a core algorithm from a PRC university must secure a license that is irrevocable and not subject to unilateral termination by the licensor, even if the university changes its research priorities. The HKEX has, in practice, rejected applications where the license contained a material adverse change (MAC) clause that could be triggered by the issuer’s financial performance post-IPO.

The SFC’s Enforcement Posture on Misrepresentation

The Securities and Futures Commission (SFC) has also weighed in, focusing on the accuracy of IP-related disclosures in prospectuses. In a 2023 enforcement action against the sponsor of a biotech listing, the SFC imposed a fine of HKD 12 million for failing to verify the chain of title for a licensed patent that was later found to be co-owned by a third-party research institute not disclosed in the application proof. The SFC’s Code of Conduct for Corporate Finance Advisors (paragraph 17.6) requires sponsors to conduct “reasonable due diligence” on the validity, enforceability, and ownership of all material IP. For a Pre-IPO company, this means the sponsor must obtain legal opinions from counsel in each jurisdiction where the IP is registered or used—typically Hong Kong, the PRC, and the United States for cross-border tech firms. The cost of this due diligence alone can run to HKD 2-5 million for a portfolio of 20+ patents, a figure that must be budgeted into the IPO timeline.

The 12-Month Survival Test in Practice

The HKEX’s 12-month survival test is the most practical hurdle. For a company licensing a patent from a third party, the Exchange will examine the license’s duration, renewal terms, and the financial impact of non-renewal. If the license has a fixed term of five years with a renewal option, the issuer must demonstrate that the renewal is virtually certain. This is typically achieved through a contractual right of first refusal or a pre-negotiated extension. In one recent application from a medical device manufacturer, the HKEX required the issuer to obtain a written undertaking from the licensor—a PRC state-owned enterprise—that it would not refuse renewal for any reason other than the issuer’s material breach. The undertaking was filed as a supplemental document to the listing application. The consequence of failing this test is a return of the application, which delays the IPO by at least six months and incurs significant advisory fees.

Structural Design: Licensing Arrangements That Pass the HKEX’s Review

Designing an IP licensing structure that satisfies the HKEX requires moving beyond standard commercial agreements. The arrangement must be engineered for regulatory resilience, not just operational efficiency.

The Exclusive, Irrevocable, and Perpetual License Model

The most defensible structure for a Pre-IPO company is an exclusive, irrevocable, and perpetual license for the core IP. This is the standard the HKEX implicitly expects. The license must grant the issuer the right to sublicense, enforce the patent against third parties, and modify the technology. In practice, this is achievable when the licensor is a related party—such as a founder’s previous company or a university spin-out—but it is difficult to negotiate with an unrelated third party. For example, a biotech firm licensing a drug delivery platform from a US university must typically pay a royalty of 2-5% of net sales. To satisfy the HKEX, the license agreement should include a clause that the royalty rate is fixed for the life of the patent and cannot be renegotiated based on the issuer’s profitability. The HKEX will also require that the license is recorded with the relevant patent office—for example, the China National Intellectual Property Administration (CNIPA) for PRC patents—to ensure priority against subsequent licensees.

The Escrow and Security Arrangement

Where an irrevocable license is not possible, the HKEX has accepted an escrow and security arrangement as a substitute. The issuer deposits a copy of the license agreement with an independent escrow agent—typically a Hong Kong-licensed trust company—and the licensor grants a security interest over the patent to the issuer. This structure was used in a 2024 listing of a PRC AI company that licensed its core algorithm from a BVI-incorporated holding company. The security interest was registered with the Hong Kong Companies Registry under the Companies Ordinance (Cap. 622), and the escrow agreement stipulated that the license could not be terminated without the issuer’s consent. The HKEX accepted this arrangement, but the sponsor was required to obtain a legal opinion confirming that the security interest was enforceable in BVI, Hong Kong, and the PRC. The total cost of structuring this arrangement was approximately HKD 1.5 million, including legal fees and escrow agent charges.

The Separation of Core and Non-Core IP

A structural solution that reduces regulatory risk is to separate the company’s core IP—the patents essential to its revenue model—from non-core IP. The core IP should be wholly owned by the listing vehicle, not licensed. This is a fundamental principle. For a company with a mixed portfolio, the HKEX will examine the contribution of each patent to revenue. If a licensed patent accounts for more than 15% of the company’s projected revenue, the Exchange will apply heightened scrutiny. In one case, a semiconductor company restructured its IP portfolio six months before its listing application, transferring ownership of its three most valuable patents from a Cayman-licensed entity to the Hong Kong operating company. The transfer was effected through a share-for-asset swap valued at HKD 50 million, which required an independent valuation and a fairness opinion from the sponsor. The restructuring cost HKD 800,000 in legal fees but eliminated the licensing risk entirely. The application was approved on the first review.

Due Diligence and Verification: The Sponsor’s Mandate

The sponsor’s role in verifying IP licensing arrangements is defined by the SFC’s Code of Conduct and reinforced by the HKEX’s listing application requirements. The process is resource-intensive and must be completed before the A1 filing.

Chain of Title Verification

The sponsor must trace the chain of title for every material licensed patent from its origin to the current licensor. This involves reviewing assignment agreements, employment invention agreements, and any prior licenses. For a patent originally filed in the PRC, the sponsor must obtain a copy of the patent certificate from CNIPA and verify that the inventor has assigned the patent to the licensor. If the inventor was an employee of a PRC university, the sponsor must also confirm that the university’s internal IP policy permits the assignment. The SFC’s 2023 enforcement case against the biotech sponsor highlighted that the failure to verify the chain of title for a single patent—which was later found to be co-owned by a government research institute—led to the sponsor’s disqualification from acting on any listing application for 12 months. The cost of chain-of-title verification for a portfolio of 10 patents is typically HKD 1-2 million, depending on the number of jurisdictions.

Third-Party Confirmation Letters

The HKEX requires that the sponsor obtain a confirmation letter from the licensor directly, not through the issuer. This letter must confirm that the license is valid, subsisting, and that the licensor has no intention of terminating it. The letter must be signed by an authorised representative of the licensor and notarised if the licensor is a PRC entity. In practice, the sponsor’s legal counsel will draft the letter and send it to the licensor’s registered address. If the licensor is a BVI company, the letter must be certified by the BVI-registered agent. The HKEX has rejected applications where the confirmation letter was signed by a director of the issuer who also served as a director of the licensor, citing a conflict of interest. The sponsor must ensure that the signatory is independent of the issuer.

The Independence of the IP Legal Opinion

The legal opinion on the validity and enforceability of the licensed IP must be obtained from a law firm that is independent of the issuer’s regular counsel. This is a specific requirement under HKEX Listing Rule 9.11(23a). The opinion must cover the patent’s validity in each jurisdiction where it is registered, the enforceability of the license terms, and the risk of third-party infringement claims. For a company with patents in the PRC, the opinion must be from a PRC-licensed law firm with a recognised IP practice. The cost of a single-jurisdiction opinion is HKD 300,000-500,000, and a multi-jurisdiction opinion covering the PRC, the US, and Europe can exceed HKD 2 million. The HKEX will request the opinion as part of the listing application, and the sponsor must be prepared to explain any qualifications or limitations in the opinion.

Case Studies: Where Licensing Arrangements Failed the HKEX Review

Examining recent rejected applications provides a practical framework for understanding the HKEX’s expectations. The following anonymised cases are based on publicly available information and industry reports.

Case One: The University Spin-Out

A biotech company licensing a drug delivery platform from a PRC university applied for a Main Board listing in 2024. The license was exclusive for a term of 10 years with a renewal option. The HKEX’s Listing Division requested additional information on the renewal terms, specifically whether the university could refuse renewal if the company’s financial performance was below expectations. The license agreement contained a clause allowing the university to terminate if the company failed to achieve certain revenue milestones. The HKEX determined that this clause created a material risk to business continuity. The application was returned, and the company spent an additional nine months renegotiating the license to remove the milestone clause. The total delay cost the company an estimated HKD 15 million in advisory fees and lost market opportunity.

Case Two: The Cross-Border Patent Pool

A semiconductor company licensed a portfolio of 15 patents from a BVI-incorporated holding company that was a related party. The license was exclusive and perpetual, but the sponsor’s due diligence revealed that the BVI company had not paid the maintenance fees for three of the patents, which had lapsed in the PRC. The HKEX required the sponsor to obtain confirmation from CNIPA that the patents could be reinstated. The reinstatement process took four months and cost HKD 200,000 in legal fees. The company was ultimately listed, but the application was delayed by six months. The lesson is that the sponsor must verify the maintenance status of every licensed patent before filing.

Case Three: The Royalty Rate Dispute

A medical device company licensed a core patent from a US entity with a royalty rate of 8% of net sales. The license agreement included a most-favoured-nation (MFN) clause, allowing the licensor to increase the royalty rate if it granted a lower rate to another licensee. The HKEX determined that the MFN clause created a financial risk that could not be quantified. The company was required to obtain a waiver from the licensor, agreeing to fix the royalty rate at 8% for the life of the patent. The waiver was obtained at a cost of USD 500,000 in a one-time payment to the licensor. The application was approved, but the additional cost reduced the company’s projected net profit by 12%.

Actionable Takeaways

1. Secure an exclusive, irrevocable, and perpetual license for all core IP before engaging a sponsor; the HKEX will not accept any termination risk tied to financial performance.
2. Budget at least HKD 3-5 million for IP due diligence, including chain-of-title verification, third-party confirmation letters, and multi-jurisdiction legal opinions, as part of the IPO readiness assessment.
3. Restructure the IP portfolio to ensure that patents contributing more than 15% of projected revenue are wholly owned by the listing vehicle, not licensed, to avoid heightened HKEX scrutiny.
4. Obtain a written undertaking from the licensor, notarised and independent of the issuer’s management, confirming non-termination for the duration of the listing, and file it as a supplemental document to the A1 application.
5. Engage a PRC-licensed law firm for CNIPA-related patent verification, and a BVI-licensed firm for Cayman or BVI entities, to ensure the legal opinion meets the independence requirement under HKEX Listing Rule 9.11(23a).